Study on Rosuvastatin+Ezetimibe and Rosuvastatin for LDL-C Goal in Patients With Recent Ischemic Stroke

PHASE4CompletedINTERVENTIONAL
Enrollment

584

Participants

Timeline

Start Date

September 9, 2019

Primary Completion Date

September 27, 2021

Study Completion Date

September 27, 2021

Conditions
Stroke, Ischemic
Interventions
DRUG

Experimental: Rosuvastatin/Ezetimibe 10

"* Rosuvastatin/Ezetimibe 10/10mg~* orally administered once daily for 90 days"

DRUG

Active Comparator: Rosuvastatin 20mg

"* Rosuvastatin 20mg~* orally administered once daily for 90 days"

Trial Locations (12)

Unknown

Korea University Ansan Hospital, Ansan-si

Hallym University Medical Center, Anyang-si

Myongji Hospital, Goyang-si

Inje University Ilsan Paik Hospital, Ilsan

Chung-Ang University Hopital, Seoul

Ewha Womans University Seoul hospital, Seoul

Korea University Guro Hospital, Seoul

Kyung-Hee University Medical Center, Seoul

Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul

Seoul National University Hospital, Seoul

Seoul St Mary's Hospital, Seoul

Severance Hospital, Yonsei University Health System, Seoul

All Listed Sponsors
collaborator

Ewha Womans University Seoul Hospital

OTHER

collaborator

Severance Hospital

OTHER

collaborator

Korea University Ansan Hospital

OTHER

collaborator

Korea University Guro Hospital

OTHER

collaborator

Myongji Hospital

OTHER

collaborator

Seoul St. Mary's Hospital

OTHER

collaborator

Samsung Medical Center

OTHER

collaborator

Seoul National University Hospital

OTHER

collaborator

Chung-Ang University Hosptial, Chung-Ang University College of Medicine

OTHER

collaborator

Hallym University Medical Center

OTHER

collaborator

Kyunghee University Medical Center

OTHER

collaborator

Inje University Ilsan Paik Hospital

OTHER

lead

Keun-Sik Hong

OTHER

NCT03993236 - Study on Rosuvastatin+Ezetimibe and Rosuvastatin for LDL-C Goal in Patients With Recent Ischemic Stroke | Biotech Hunter | Biotech Hunter